ReviewCurrent pharmaceutical design2009
Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
Review in Current pharmaceutical design, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality.Epilepsia · 2021Pooled it
- The adiponectin-depression nexus: a brief review of mechanisms and therapeutic opportunities.Metabolic brain disease · 2026Review
- A narrative review of the effects of dexamethasone on traumatic brain injury in clinical and animal studies: focusing on inflammation.Inflammopharmacology · 2023Review
- Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule.World journal of psychiatry · 2021Review
- Guanine-Based Purines as an Innovative Target to Treat Major Depressive Disorder.Frontiers in pharmacology · 2021Article
- Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-stroke depression.Therapeutic advances in psychopharmacology · 2020Review
- Neuronal nitric oxide synthase and affective disorders.IBRO reports · 2018Review
- Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Elevated Glutamate and Glutamine Levels in the Cerebrospinal Fluid of Patients With Probable Alzheimer's Disease and Depression.Frontiers in psychiatry · 2018Article
- New targets for rapid antidepressant action.Progress in neurobiology · 2017Review
- Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.Expert review of clinical pharmacology · 2017Review
- Brain-Specific SNAP-25 Deletion Leads to Elevated Extracellular Glutamate Level and Schizophrenia-Like Behavior in Mice.Neural plasticity · 2017Article
- GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.Bipolar disorders · 2016Article
- Baseline effects of transcranial direct current stimulation on glutamatergic neurotransmission and large-scale network connectivity.Brain research · 2015Article
- Article
- Article
- Article
- Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2).Epilepsy & behavior : E&B · 2013Review
- Ketamine regulates the presynaptic release machinery in the hippocampus.Journal of psychiatric research · 2013Article
- Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
There have been no recent advances in drug development for mood disorders in terms of identifying drug targets that are mechanistically distinct from existing ones. As a result, existing antidepressants are based on decades-old notions of which targets are relevant to the mechanisms of antidepressant action. Low rates of remission, a delay of onset of therapeutic effects, continual residual depressive symptoms, relapses, and poor quality of life are unfortunately common in patients with mood disorders. Offering alternative options is requisite in order to reduce the individual and societal burden of these diseases. The glutamatergic system is a promising area of research in mood disorders, and likely to offer new possibilities in therapeutics. There is increasing evidence that mood disorders are associated with impairments in neuroplasticity and cellular resilience, and alterations of the glutamatergic system are known to play a major role in cellular plasticity and resilience. Existing antidepressants and mood stabilizers have prominent effects on the glutamate system, and modulating glutamatergic ionotropic or metabotropic receptors results in antidepressant-like properties in animal models. Several glutamatergic modulators targeting various glutamate components are currently being studied in the treatment of mood disorders, including release inhibitors of glutamate, N-methyl-D-aspartate (NMDA) antagonists, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) throughput enhancers, and glutamate transporter enhancers. This paper reviews the currently available knowledge regarding the role of the glutamatergic system in the etiopathogenesis of mood disorders and putative glutamate modulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.